Pulsenmore Ltd. (Pulsenmore (PLSM)) is having a bit of a hangover Friday. After a wild rally earlier this week, the home ultrasound company announced a $7.5 million private placement, and investors are taking some profits off the table.

The Ramat Gan, Israel-based company said it struck a deal with a single healthcare-focused institutional investor to sell 1,562,500 ordinary shares and warrants to buy another 1,562,500 shares, all at a combined price of $4.80 per share. That's above the Nasdaq minimum price requirement, so no worries about compliance there. The deal is expected to close Friday, and after fees, Pulsenmore will pocket roughly $7.5 million.

CEO Elazar Sonnenschein said the cash will help fund the company's next growth phase, especially in the U.S. market. "We plan to use the proceeds to expand our commercial presence, increase market penetration, and advance strategic initiatives," he explained. More specifically, the money will go toward marketing, commercialization, and general working capital.

The stock was down about 9.4% in premarket trading Friday, sitting at $5.345. That's a pullback from Wednesday, when shares shot up more than 200% after Pulsenmore announced a partnership with Ouma Health. The two companies are integrating Pulsenmore's FDA-authorized home ultrasound platform into Ouma's virtual maternity care model across the U.S.

So, is this a buying opportunity or a sign that the rally was overdone? The private placement dilutes existing shareholders a bit, but the funds are earmarked for growth. And with a major partnership in place, Pulsenmore has a clearer path to scale. Investors will be watching to see if the company can turn this momentum into real market share.